Management of toxic optic neuropathy via a combination of Wharton’s jelly-derived mesenchymal stem cells with electromagnetic stimulation

Table 2 Group2: Demonstration of demographic characteristics, structural and functional changes of group2 to which only rEMS was applied

Patient no	Eye	Toxin	BCVA		Visual Field FPDI		GCC Thickness		VEP P100 lat		VEP P100 ampl
Patient no	Eye	Toxin	Before	After	Before	After	Before	After	Before	After	Before	After
1	R	Methanol	80	89	61	71	103	91	129	114	3.2	4.7
2	L	Methanol	35	80	13	42	88	78	144	126	2.2	3.4
3	R	Amiodaron	90	100	49	72	112	108	131	110	3.5	4.1
4	R	Methanol	35	50	46	53	74	58	156	128	1.0	2.1
5	L	Sildenafil	60	74	42	56	89	64	141	119	2.0	2.9
6	R	Methanol	50	74	40	52	88	74	137	120	3.0	4.1
7	L	CO₂	40	50	13	17	74	59	138	124	3.7	4.3
8	L	Methanol	35	35	12	12	57	52	144	141	2.9	2.9
9	L	Methanol	45	45	7	8	65	53	154	155	1.7	1.6
10	L	Methanol	59	59	8	8	62	59	146	145	1.6	1.4
11	R	Methanol	36	36	3	2	58	57	153	150	1.7	1.7
12	L	Methanol	39	39	2	2	56	54	152	151	1.3	1.3

rEMS repetitive electromagnetic stimulation, BCVA best corrected visual acuity (ETDRS letters), FPDI fundus perimetry deviation index (%), GCC thickness Ganglion cell complex (µm), VEP visual evoked potential, P100 lat latency (ms), P100 ampl amplitude (mV)

ISSN: 1757-6512